ReviewCurrent opinion in immunology2009
The immunology of smallpox vaccines.
Review in Current opinion in immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 114 citations in OpenAlex.
- Early Pro-Inflammatory Signal and T-Cell Activation Associate With Vaccine-Induced Anti-Vaccinia Protective Neutralizing Antibodies.Frontiers in immunology · 2021Trial
- Emerging strategies for monkeypox: antigen and antibody applications in diagnostics, vaccines, and treatments.Military Medical Research · 2025Review
- Cost-effectiveness of vaccination strategies to control future mpox outbreaks in England: a modelling study.The Lancet regional health. Europe · 2025Article
- A review of Mpox: Biological characteristics, epidemiology, clinical features, diagnosis, treatment, and prevention strategies.Exploration (Beijing, China) · 2025Review
- Biological threat preparedness through vaccine development and stockpiling: challenges and strategic implications.Frontiers in public health · 2025Review
- Review
- Potential use of cidofovir, brincidofovir, and tecovirimat drugs in fighting monkeypox infection: recent trends and advancements.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Neutralization Determinants on Poxviruses.Viruses · 2023Review
- Viral Prototypes for Pandemic Preparedness: The Road Ahead.The Journal of infectious diseases · 2023Article
- Monkeypox: a review of epidemiological modelling studies and how modelling has led to mechanistic insight.Epidemiology and infection · 2023Review
- Multinational monkeypox outbreak: what do we know and what should we do?Irish journal of medical science · 2023Article
- Indirect Dispersion of SARS-CoV-2 Live-Attenuated Vaccine and Its Contribution to Herd Immunity.Vaccines · 2023Review
- Orthopoxvirus Zoonoses-Do We Still Remember and Are Ready to Fight?Pathogens (Basel, Switzerland) · 2023Review
- The re-emergence and transmission of Monkeypox virus in Nigeria: the role of one health.Frontiers in public health · 2023Article
- Monkeypox: a global health emergency.Frontiers in microbiology · 2023Review
- Review
- Defining antigen targets to dissect vaccinia virus and monkeypox virus-specific T cell responses in humans.Cell host & microbe · 2022Article
- Prevention of monkeypox with vaccines: a rapid review.The Lancet. Infectious diseases · 2022Review
- Poxviruses and the immune system: Implications for monkeypox virus.International immunopharmacology · 2022Review
- The immune response to lumpy skin disease virus in cattle is influenced by inoculation route.Frontiers in immunology · 2022Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
In spite of the eradication of smallpox over 30 years ago; orthopox viruses such as smallpox and monkeypox remain serious public health threats both through the possibility of bioterrorism and the intentional release of smallpox and through natural outbreaks of emerging infectious diseases such as monkeypox. The eradication effort was largely made possible by the availability of an effective vaccine based on the immunologically cross-protective vaccinia virus. Although the concept of vaccination dates back to the late 1800s with Edward Jenner, it is only in the past decade that modern immunologic tools have been applied toward deciphering poxvirus immunity. Smallpox vaccines containing vaccinia virus elicit strong humoral and cellular immune responses that confer cross-protective immunity against variola virus for decades after immunization. Recent studies have focused on: establishing the longevity of poxvirus-specific immunity, defining key immune epitopes targeted by T and B cells, developing subunit-based vaccines, and developing genotypic and phenotypic immune response profiles that predict either vaccine response or adverse events following immunization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.